Literature DB >> 28650536

Surveillance for lung metastasis from giant cell tumor of bone.

Mamer Rosario1,2, Han-Soo Kim1, Ji Yeon Yun1, Ilkyu Han1.   

Abstract

BACKGROUND AND OBJECTIVES: Literature on surveillance for lung metastasis from giant cell tumor of bone (GCTB) is scarce. We aimed to develop one by determining: (1) the optimal surveillance schedule by analyzing time-to-event data, taking into account the predictive factors, and (2) the effective diagnostic modality.
METHODS: A total of 333 patients who underwent surgery for GCTB were followed for at least 2 years. All had chest radiography, and 169 had additional CT for surveillance. Time to lung metastasis and cumulative incidence were calculated, and diagnostic performance between chest radiography and CT was compared.
RESULTS: Twenty-five (7.5%) of 333 patients developed lung metastasis, and local recurrence (LR) was the only predictive factor (RR = 6.54). Median interval from LR to metastasis was 15 months, and 17 (85%) of the 20 metastases with LR occurred within 3 years of LR. Cumulative post-LR incidences at 1, 3, and 5 years were 15.4%, 21.5%, and 21.5%, respectively. CT was more sensitive (100% vs 32%), and had higher positive predictive value (81% vs 57%) and accuracy (96% vs 93%).
CONCLUSIONS: Intensified lung surveillance is warranted for GCTB patients with LR, especially for 3 years from diagnosis of LR. CT is effective for detecting lung metastasis from GCTB.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  chest CT; chest radiography; giant cell tumor; local recurrence; lung metastasis; surveillance guideline

Mesh:

Year:  2017        PMID: 28650536     DOI: 10.1002/jso.24739

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Giulio Leone; Alberto Righi; Manabu Akahane; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  Int Orthop       Date:  2018-08-11       Impact factor: 3.075

2.  H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.

Authors:  Lihua Gong; Marilyn M Bui; Wen Zhang; Xiaoqi Sun; Ming Zhang; Ding Yi
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

Review 3.  Biology of Bone Sarcomas and New Therapeutic Developments.

Authors:  Hannah K Brown; Kristina Schiavone; François Gouin; Marie-Françoise Heymann; Dominique Heymann
Journal:  Calcif Tissue Int       Date:  2017-12-13       Impact factor: 4.333

4.  Giant cell tumor of bone: Unusual features of a rare tumor.

Authors:  Ziyad M Mohaidat; Hisham Z Al-Jamal; Audai M Bany-Khalaf; Ahmad M Radaideh; Ziad A Audat
Journal:  Rare Tumors       Date:  2019-09-25

5.  Outcome of lung metastases due to bone giant cell tumor initially managed with observation.

Authors:  Shinji Tsukamoto; Giovanni Ciani; Andreas F Mavrogenis; Cristina Ferrari; Manabu Akahane; Yasuhito Tanaka; Michele Rocca; Alessandra Longhi; Costantino Errani
Journal:  J Orthop Surg Res       Date:  2020-11-07       Impact factor: 2.359

6.  Recurrent Giant Cell Tumor of Distal Radius with Pulmonary Metastasis: A Case Report.

Authors:  Satvik N Pai; Srinivasan Rajappa
Journal:  J Orthop Case Rep       Date:  2021-12

Review 7.  Metastatic giant cell tumour of bone: a narrative review of management options and approaches.

Authors:  Ruiwen Xu; Peter F M Choong
Journal:  ANZ J Surg       Date:  2022-02-10       Impact factor: 2.025

8.  Premalignant Conditions of Bone.

Authors:  Michael D Eckhoff; Matthew E Wells; Osvaldo Padilla; Elizabeth M Polfer; Christopher J Castagno; Ahmed M Thabet; Shaimaa Elzamly; Harry L Wilson; Rajiv Rajani
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-10-13

9.  Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation.

Authors:  Jiang Yafei; Mu Haoran; Jiang Wenyan; Xue Linghang; Tian Kai; Wang Gangyang; Wang Zhuoying; Han Jing; Yang Mengkai; Tang Yujie; Hua Yingqi; Cai Zhengdong
Journal:  J Orthop Translat       Date:  2021-06-01       Impact factor: 5.191

10.  Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone.

Authors:  Yi Luo; Fan Tang; Yitian Wang; Yong Zhou; Li Min; Wenli Zhang; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Cancer Manag Res       Date:  2018-07-05       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.